

S2 Table. Post-consolidation: low risk

Drug	Dose	Days
Interim maintenance (11 wk)		
Vincristine (IV)	1.5 mg/m ² (max. 2 mg)	1, 15
Methotrexate (IV) ^{a)}	5 g/m ²	1, 15
6-Mercaptopurine (PO)	60 mg/m ²	29-77
Methotrexate (IT)	By age ^{b)}	1
Delayed intensification (8 wk)		
Vincristine (IV)	1.5 mg/m ² (max. 2 mg)	1, 15, 29, 43
Daunorubicin (IV)	30 mg/m ²	1, 29
Cytarabine (IV)	100 mg/m ²	1-5, 29-33
Cyclophosphamide (IV)	1,200 mg/m ²	15, 43
l-Asparaginase (IM)	6,000 u/m ² (max, 10,000 u)	16, 18, 20, 44, 46, 48
Prednisolone (PO)	45 mg/m ² (max. 60 mg)	1-5, 15-19, 29-33, 43-47
Methotrexate (IT)	By age ^{b)}	1, 29

Schema: IM#1 (HD-MTX x2) → DI#1 → Maint. DI, delayed intensification; HD-MTX, high dose methotrexate; IM, intramuscular; IT, intrathecal; IV, intravenous; Maint., maintenance; PO, per os. ^{a)}Maintenance treatment begins and ends with HD-methotrexate (3 g/m² IV), vincristine (1.5 mg/m² IV), prednisolone (45 mg/m² PO for 5 days), and IT methotrexate; the last course of chemotherapy is HD-methotrexate. A total of nine courses of HD-methotrexate are administered during maintenance treatment. Oral methotrexate (25 mg/m² weekly) is omitted during the week of HD-methotrexate treatment. The regimen of maintenance treatment is common for all patients, ^{b)}Age-adjusted doses of intrathecal methotrexate: 6 mg (<1 year), 7.5 mg (≥ 1 and < 2 years), 10 mg (≥ 2 and < 3 years), 12.5 mg (≥ 3 years).